ICLR | Ticker Profile - Titan Protect

ICLR

ICON Public Limited Company

Healthcare · Diagnostics & Research · NMS

$149.45

Data: 2026-05-14

✗ ETHICAL FAIL

WEAK MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$9.1B

Total market value of the company

Trailing P/E

16.44

Reasonably valued

Forward P/E

10.24

Based on estimated future earnings — lower means cheaper

Rev Growth

+0.6%

Year-over-year revenue change

Profit Margin

7.4%

How much profit the company keeps from each dollar of revenue

ROE

6.3%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$137.21

-8% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 14 analysts covering this stock

About ICON Public Limited Company

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.

https://www.iconplc.com

Country: Ireland Employees: 39,800 Industry: Diagnostics & Research

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

39.1% FAIL

Debt must be below 33% of total assets

Cash Ratio

5.1% PASS

Interest-bearing cash below 33% of assets

Receivables

0.0% PASS

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Valuation

Fair Value Est.

$172.02

What our model estimates this business is worth per share

Margin of Safety

13.1%

Slight discount to fair value

Rating

AVOID

Overall assessment combining ethics, valuation, and quality

Percentile

38.0th

Ranks in the top 62% of our 13,571 screened universe

Ethical Score

10.0

Valuation Score

88.0

Quality Score

45.3

Combined

N/A

Trading at $117 against a fair value of $172, a 32% discount. Fails ethical screen (Debt ratio). Ranks better than 68% of screened stocks.

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

-0.618

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0698

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.529

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-40.7%

Historical annualised return based on price data

Max Drawdown

-76.9%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.23

Moves slightly more than the broader market

52W High

$211.00

29% below the year high

52W Low

$66.57

125% above the year low

Avg Volume

1,314,824

Average daily shares traded — higher means easier to buy and sell

Short Ratio

2.0

Days it would take all short sellers to cover — higher means more crowded

Short % Float

3.5%

Low short interest — limited bearish positioning

Div Yield

0.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$7.14

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.38

Conservative use of debt — low financial risk

Current Ratio

1.06

Adequate but worth monitoring

Quick Ratio

1.02

Like current ratio but excludes inventory — stricter test

Gross Margin

28.2%

Revenue left after cost of goods — higher means pricing power

Operating Margin

12.7%

Profit from core operations before interest and tax

Free Cash Flow

$925M

Positive — the business generates more cash than it spends

Revenue (TTM)

$8.1B

Total revenue over the last 12 months

Net Income

$599M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$180.00

Target Median

$137.21

Target Low

$90.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-14

Before you go